VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Jan. 22, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has progressed into the randomized portion of its Phase II human clinical trial evaluating the Company’s product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. The Company also announced the selection of the 300 mg dose, the highest one tested, in the randomized portion of the trial.
